Portfolio
1 totalCo-Investors
7Latest Pulse
- Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in ImmunologyTriveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.→
- Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology TherapeuticsTriveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.→